Payment overview · 2025
General Payments
$17.55
1 reported records · 1 companies
Healthcare provider profile · identity verified
Timothy Allen Pratt, MD
Allopathic & Osteopathic Physicians|Family Medicine · SHEFFIELD, IL · NPI 1073719357
Verified facts
What the public records show
CMS Open Payments records show Timothy Allen Pratt, MD received $17.55 in general payments during 2025 across 1 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.55 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $17.55 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 742 | 215 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 473 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 433 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 397 | 100 |
| Omeprazole | Omeprazole | 341 | 90 |
| Lisinopril | Lisinopril | 324 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 304 | 91 |
| Gabapentin | Gabapentin | 294 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 288 | 74 |
| Furosemide | Furosemide | 278 | 66 |
| Metformin Hcl | Metformin Hcl | 217 | 60 |
| Losartan Potassium | Losartan Potassium | 192 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 190 | 57 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 176 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 46 |
| Lorazepam | Lorazepam | 168 | 49 |
| Potassium Chloride | Potassium Chloride | 167 | 46 |
| Prednisone | Prednisone | 158 | 77 |
| Alprazolam | Alprazolam | 155 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 153 | 33 |
| Warfarin Sodium | Warfarin Sodium | 147 | 31 |
| Tramadol Hcl | Tramadol Hcl | 143 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 54 |
| Sertraline Hcl | Sertraline Hcl | 137 | 45 |
| Eliquis | Apixaban | 128 | 30 |
| Pregabalin | Pregabalin | 123 | 28 |
| Trazodone Hcl | Trazodone Hcl | 121 | 31 |
| Allopurinol | Allopurinol | 117 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 35 |
| Metformin Hcl Er | Metformin Hcl | 112 | 32 |
| Mirtazapine | Mirtazapine | 111 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 29 |
| Atenolol | Atenolol | 105 | 26 |
| Montelukast Sodium | Montelukast Sodium | 99 | 25 |
| Glipizide Er | Glipizide | 96 | 22 |
| Baclofen | Baclofen | 95 | 27 |
| Meloxicam | Meloxicam | 95 | 28 |
| Donepezil Hcl | Donepezil Hcl | 94 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 92 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 19 |
| Cephalexin | Cephalexin | 85 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 24 |
| Alendronate Sodium | Alendronate Sodium | 77 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 17 |
| Simvastatin | Simvastatin | 70 | 24 |
| Clonazepam | Clonazepam | 69 | 12 |
| Enalapril Maleate | Enalapril Maleate | 68 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 15 |
| Chlorthalidone | Chlorthalidone | 62 | 15 |
| Clonidine Hcl | Clonidine Hcl | 59 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 12 |
| Bupropion Xl | Bupropion Hcl | 52 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 15 |
| Spironolactone | Spironolactone | 50 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 13 |
| Synthroid | Levothyroxine Sodium | 44 | 14 |
| Terazosin Hcl | Terazosin Hcl | 44 | 12 |
| Carvedilol | Carvedilol | 43 | 14 |
| Famotidine | Famotidine | 42 | suppressed |
| Methadone Hcl | Methadone Hcl | 42 | suppressed |
| Jardiance | Empagliflozin | 41 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 14 |
| Nystatin | Nystatin | 37 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Fentanyl | Fentanyl | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Klor-Con M20 | Potassium Chloride | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 16 |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 20 |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Phenytoin | Phenytoin | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 25 |
| Metolazone | Metolazone | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Fluocinonide | Fluocinonide | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 12 |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 11 |
| Estradiol | Estradiol | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Enbrel Sureclick | Etanercept | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $17.55 · 1 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error